InterMune Ends Drug Trial

InterMune Inc.'s (ITMN) late stage trial of Actimmune failed to improve survival rates in idiopathic pulmonary fibrosis patients prompting the biotechnology company to end clinical trials. The stock price plunged $5.90 to close at $22.15.